[Revision of the recommendations of the Commission on Pharmacotherapy of the German Society for Rheumatology. Comment on the use of Orthokin].
Due to the public discussion on the drug "Orthokin", the Commission for Pharmacotherapy of the German Society for Rheumatology (Deutschen Gesellschaft für Rheumatologie, DGRh) has summarized the relevant data. An unpublished study with 400 patients shows an advantage for Orthokin compared to either hyaluronic acid or a placebo for the treatment of osteoarthritis related chronic knee pain. Until these data have been published in an appropriate specialist journal, it is not possible for the DGRh to give a recommendation.
Burmester
G R
GR
Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Charité- Universitätsmedizin Berlin. gerd.burmester@charite.de
Grifka
J
J
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D006801:Humans; D020370:Osteoarthritis, Knee / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors*
D018501:Antirheumatic Agents; D017472:Receptors, Interleukin-1